Evidence map›Paper›PMID 31444655›Full record

ReviewCurrent treatment options in oncology2019

Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.

J Stuart Ferriss, M Yvette Williams-Brown

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Diagnostics of Mutations in MMR/Diagnostics (Basel, Switzerland) · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

J Stuart FerrissDepartment of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Phipps 281, Baltimore, MD, 21287, USA. jferris3@jhmi.edu.
M Yvette Williams-BrownDepartments of Women's Health and Oncology, The University of Texas at Austin Dell Medical School, 1301 W 38th St, Suite 705, Austin, TX, 78705, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementResearch into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.

Indexed as

Molecular Targeted TherapyAntineoplastic Agents, ImmunologicalBiomarkers, TumorColorectal Neoplasms, Hereditary NonpolyposisDisease SusceptibilityFemaleGenital Neoplasms, FemaleHumansImmunotherapyTumor MicroenvironmentAntineoplastic Agents, ImmunologicalBiomarkers, TumorCheckpoint inhibitorsEndometrial cancerGynecologic cancersImmunotherapyLynch syndromeOvarian cancerPD-1PD-L1

Identifiers

PMID31444655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.